Systemic Lupus Erythematosus (SLE) is a disease in which the immune system attacks the
healthy cells and tissues, causing inflammation that can damage organs in the body. About 50%
of SLE patients experience inflammation in the kidneys. The purpose of this study is to
determine the effectiveness and safety of two dosing arms of ACTHar gel in treating
proliferative Lupus Nephritis (LN). This study hypothesizes that both dosing arms of ACTHar
are safe and effective in treating proliferative LN (Class III and IV).